Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1380.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,532.0,1.0,=,2.6
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1963.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,362.0,1.0,=,5.4
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1010.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,351.0,1.0,=,2.9
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1305.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,298.0,1.0,=,4.4
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1879.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,535.0,1.0,=,3.5
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,2028.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,322.0,1.0,=,6.3
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,856.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,273.0,1.0,=,3.1